Welcome to our dedicated page for Solana Company SEC filings (Ticker: HSDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solana Company filings document a Delaware issuer with Nasdaq-listed Class A common stock and a business profile that includes a Solana (SOL) digital asset treasury following its history as Helius Medical Technologies. Recent 8-K reports cover operating results, staking-reward revenue, digital-asset fair value effects, capital actions, registered-direct equity financing, put-option arrangements, and outstanding common stock and pre-funded warrants.
Governance filings include director and officer changes, separation and employment arrangements, board composition, and definitive proxy materials for annual-meeting matters, executive compensation, equity awards, and shareholder voting items. The filings also describe the company’s expansion from its medical-device neurotechnology legacy into SOL holdings, staking, custody, and related infrastructure initiatives.
Solana Co director Lee Michel Kai Tai filed an amended initial insider report for the company, which trades under ticker HSDT. This Form 3/A identifies his status as a director but shows no reported purchases, sales, or other transactions in the company’s securities.
Solana Co director Sergio Mello has filed an initial Form 3 insider ownership report for HSDT. The filing lists him as a director of the company and does not report any insider transactions or derivative positions in this submission.
Solana Company is selling 3,076,922 shares of Class A common stock in a registered direct offering at $2.60 per share for a total offering price of $7,999,997.20, with delivery expected on or about April 28, 2026.
The company expects net proceeds of approximately $7.9 million to be used for accumulating SOL, working capital, general corporate purposes, business expansion and strategic initiatives. The offering is made under a Form S-3 shelf registration and assumes no exercise of outstanding warrants.
Solana Company entered into securities purchase agreements for a registered direct offering of 3,076,922 shares of Class A common stock at $2.60 per share, generating expected gross proceeds of about $8 million and net proceeds of about $7.9 million.
The company plans to use the cash to accumulate SOL tokens, fund working capital, support general corporate purposes, business expansion and other strategic initiatives. In connection with the deal, Solana Company granted purchasers put options allowing them, upon specified future events, to require the company to repurchase their shares at the original purchase price plus an internal rate of return of 7.0% per annum.
Solana Company reported upcoming changes to its Board of Directors. Sherrie Perkins and Paul Buckman told the company they will not stand for re-election when their current terms end at the 2026 Annual Meeting of Stockholders on May 21, 2026. The company states their decisions are not due to any disagreement over operations, policies, practices, strategy, management, or the Board.
On April 23, 2026, the Board increased its size from seven to nine members and appointed Michel Lee and Sergio Mello to fill the new seats, effective immediately. Both will receive cash and equity compensation under the existing non-employee director compensation policy and will be covered by the company’s standard indemnification agreement for directors and officers.
Solana Company announced that Antonella Favit‑Van Pelt, MD, PhD, has mutually agreed with the company to resign as Chief Medical Officer, effective April 8, 2026. The parties entered into a Separation Agreement effective the same date.
Under this agreement, Dr. Favit‑Van Pelt will receive a lump‑sum separation payment of $875,000, less applicable withholdings, to be paid within ten business days after the effective date. In return, she waives and releases employment‑related claims and must continue to honor confidentiality and invention assignment obligations from her employment agreement.
Solana Company is soliciting proxies for its 2026 Annual Meeting of Stockholders, to be held virtually on May 21, 2026 at 9:00 a.m. ET. Holders of its Class A common stock as of April 1, 2026, when 54,889,569 shares were outstanding, may vote.
Stockholders will elect seven directors and vote on ratifying CBIZ as independent registered public accounting firm for the year ending December 31, 2026. The board recommends voting FOR all director nominees and FOR Proposal 2.
The filing details board independence, leadership structure and committee assignments, and outlines executive pay. In 2025, CEO Dane Andreeff received total compensation of $2.1 million, CFO Jeffrey Mathiesen received $1.5 million, and Executive Chairman Joseph Chee received $6.9 million, including 1,109,118 RSUs tied to a 2025 private placement and digital asset treasury work. The proxy also describes change-in-control severance protections, a clawback policy for erroneously awarded compensation, and the company’s insider trading and board governance policies.
Solana Company appointed Agustina “Madelene” Gani Tjandrasuwita as Chief Operating Officer and Deputy Chief Financial Officer, effective April 6, 2026. She brings more than 25 years of global finance experience across crypto, fintech, and public companies, including senior roles at Hedera Hashgraph, Aptos Labs, Gemini, and JUUL Labs.
Under an Offer Letter dated March 13, 2026, she will receive a $350,000 annual base salary, be eligible for an annual target bonus equal to 40% of base salary, and additional equity incentives with a combined target value of $300,000 to $500,000. After three months, subject to board approval, she is also eligible for a one-time stock option grant with a grant date fair value of $75,000, vesting over four years.